Skip to content
OpenCapital
Get started

Castle Biosciences CSTL Share-Based Payment - Unrecognized Cost of Nonvested Awards

Share-Based Payment - Unrecognized Cost of Nonvested Awards at other companies

GeneDx Holdings logo
GeneDx HoldingsWGS
$0-100%
BillionToOne, Inc. logo
BillionToOne, Inc. BLLN
$85.2M—

Other financials

Income statement

See full
Revenue$83.7M-4.9%
Gross profit$63.1M-11.8%
Operating income-$18.4M+34.1%
Net income-$14.5M+43.8%
EPS (diluted)-$0.49+45.6%

Balance sheet

See full
Cash & equivalents$63.8M-28.9%
Total debt$36.7M+42.1%
Total equity$461.4M+4.8%
Total assets$547.8M+9.2%

Cash flow

See full
Operating cash flow-$22.1M-267%
CapEx$12.5M+163%
Free cash flow-$34.6M-221%

Valuation

See full
Market cap$694.86M+29.9%
Enterprise value$667.82M+41.8%
P/S2×+0.5×

Profitability

See full
Gross margin77.9%-4.1pp
Operating margin-9.8%-30.8pp
Net margin-3.8%-10.2pp
FCF margin1.3%-10.7pp

Returns & leverage

See full
Return on equity-2.8%-10.6pp
Debt / equity0.1×0.0×
Current ratio6.7×-2.6×

Where this comes from

Reported directly by Castle Biosciences in its filing.

Tagged under the XBRL concept us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized.

The official record: Castle Biosciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Castle Biosciences's share-based payment - unrecognized cost of nonvested awards.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Castle Biosciences's share-based payment - unrecognized cost of nonvested awards?
Castle Biosciences (CSTL) reported share-based payment - unrecognized cost of nonvested awards of $94.5M in Q1 2026.
How has Castle Biosciences's share-based payment - unrecognized cost of nonvested awards changed year-over-year?
Castle Biosciences's share-based payment - unrecognized cost of nonvested awards increased by 6.5% year-over-year, from $88.7M to $94.5M.
What does share-based payment - unrecognized cost of nonvested awards mean?
This represents the total compensation expense for equity-based awards that has been granted but not yet recognized in the income statement because the vesting conditions have not been met. It serves as a forward-looking indicator of future non-cash compensation expenses. Investors use this to forecast the impact of stock-based compensation on future earnings.